Isradipine, a dihydropyridine calcium-channel (CaV1.3) blocker approved for the treatment of hypertension, is neuroprotective in animal models of PD (Chan et al. 2007; Guzman et al. 2010; Ilijic et al. 2011). This evidence concerns the gene CACNA1D and Parkinson disease.